



(51) International Patent Classification:

C12P 21/00 (2006.01) C12N 5/10 (2006.01)
C12N 9/24 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/EP2014/068946

(22) International Filing Date:

5 September 2014 (05.09.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13183124.0 5 September 2013 (05.09.2013) EP

(71) Applicants: VIB VZW [BE/BE]; Rijvisschestraat 120, B-9052 Gent (BE). UNIVERSITEIT GENT [BE/BE]; Sint-Pietersnieuwstraat 25, B-9000 Gent (BE).

(72) Inventors: CALLEWAERT, Nico; Begijnhoflaan 15, B-9850 Nevele (BE). SANTENS, Francis; Kriktestraat 18, B-9160 Lokeren (BE).

(74) Common Representative: VIB VZW; Rijvisschestraat 120, B-9052 Gent (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2015/032899 A1

(54) Title: CELLS PRODUCING FC CONTAINING MOLECULES HAVING ALTERED GLYCOSYLATION PATTERNS AND METHODS AND USE THEREOF

(57) Abstract: The present application relates to the field of glyco-engineering, more specifically to glyco-engineering of Fc containing molecules, such as antibodies. It is shown herein that Fc containing molecules with a specific glycosylation pattern have a considerably longer circulating half-life in vivo, without having an altered binding affinity for their respective antigen. This has therapeutic implications in reducing the frequency with which these molecules need to be administered, without affecting therapeutic efficacy. Also, cells are provided that can produce the Fc molecules with the desired glycosylation pattern.